Compare IMNM & SPNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMNM | SPNT |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2020 | 2013 |
| Metric | IMNM | SPNT |
|---|---|---|
| Price | $17.97 | $25.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 5 |
| Target Price | ★ $35.19 | $28.75 |
| AVG Volume (30 Days) | ★ 1.4M | 707.5K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.40 | ★ 250.00 |
| EPS | N/A | ★ 1.40 |
| Revenue | $6,941,000.00 | ★ $3,205,100,000.00 |
| Revenue This Year | N/A | $3.57 |
| Revenue Next Year | $18,803.97 | $5.58 |
| P/E Ratio | ★ N/A | $18.46 |
| Revenue Growth | N/A | ★ 23.09 |
| 52 Week Low | $14.64 | $17.71 |
| 52 Week High | $30.06 | $26.50 |
| Indicator | IMNM | SPNT |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | 60.25 |
| Support Level | $17.83 | $22.22 |
| Resistance Level | $23.48 | $26.30 |
| Average True Range (ATR) | 0.98 | 0.60 |
| MACD | 0.14 | 0.07 |
| Stochastic Oscillator | 32.67 | 76.04 |
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.